

POLYMYXIN B- polymyxin b sulfate injection, powder, for solution
Xellia Pharmaceuticals USA LLC

POLYMYXIN B for INJECTION, USP
500,000 Units/vial

Rx ONLY

To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.

WARNING

CAUTION: WHEN THIS DRUG IS GIVEN INTRAMUSCULARLY AND/OR INTRATHECALLY, IT SHOULD BE GIVEN ONLY TO HOSPITALIZED PATIENTS, SO AS TO PROVIDE CONSTANT SUPERVISION BY A PHYSICIAN.

RENAL FUNCTION SHOULD BE CAREFULLY DETERMINED AND PATIENTS WITH RENAL DAMAGE AND NITROGEN RETENTION SHOULD HAVE REDUCED DOSAGE. PATIENTS WITH NEPHROTOXICITY DUE TO POLYMYXIN B SULFATE USUALLY SHOW ALBUMINURIA, CELLULAR CASTS, AND AZOTEMIA.

DIMINISHING URINE OUTPUT AND A RISING BUN ARE INDICATIONS FOR DISCONTINUING THERAPY WITH THIS DRUG.

NEUROTOXIC REACTIONS MAY BE MANIFESTED BY IRRITABILITY, WEAKNESS, DROWSINESS, ATAXIA, PERIORAL PARESTHESIA, NUMBNESS OF THE EXTREMITIES, AND BLURRING OF VISION. THESE ARE USUALLY ASSOCIATED WITH HIGH SERUM LEVELS FOUND IN PATIENTS WITH IMPAIRED RENAL FUNCTION AND/OR NEPHROTOXICITY.

THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED.

THE NEUROTOXICITY OF POLYMYXIN B SULFATE CAN RESULT IN RESPIRATORY PARALYSIS FROM NEUROMUSCULAR BLOCKADE, ESPECIALLY WHEN THE DRUG IS GIVEN SOON AFTER ANESTHESIA AND/OR MUSCLE RELAXANTS.

USAGE IN PREGNANCY: THE SAFETY OF THIS DRUG IN HUMAN PREGNANCY HAS NOT BEEN ESTABLISHED.

DESCRIPTION

Polymyxin B for Injection is one of a group of basic polypeptide antibiotics derived from *B. polymyxa* (*B. aerospirous*). Polymyxin B sulfate is the sulfate salt of Polymyxins B₁ and B₂, which are produced by the growth of *Bacillus polymyxa* (Prazmowski) Migula (Fam. Bacillacea). It has a potency of not less than 6000 polymyxin B units per mg, calculated

INDICATIONS AND USAGE

Acute Infections Caused by Susceptible Strains of *Pseudomonas aeruginosa*.

Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and blood-stream caused by susceptible strains of *Ps. aeruginosa*. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of *Ps. aeruginosa*. It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated:

H influenzae, specifically meningeal infections.

Escherichia coli, specifically urinary tract infections.

Aerobacter aerogenes, specifically bacteremia.

Klebsiella pneumoniae, specifically bacteremia.

NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

CONTRAINDICATIONS

This drug is contraindicated in persons with a prior history of hypersensitivity reactions to polymyxins.

WARNINGS

Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Polymyxin B for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of *C. difficile*.

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of *C. difficile* cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

If CDAD is suspected or confirmed, ongoing antibiotic use not directed against *C. difficile* may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of *C. difficile*, and surgical evaluation should be instituted as clinically indicated.

Electrolyte and Acid/Base Abnormalities

Postmarketing cases of renal tubulopathy (i.e., Pseudo-Bartter syndrome) have been identified with the use of intravenous polymyxins, including polymyxin B (see **ADVERSE REACTIONS**). All cases reported hypokalemia and metabolic alkalosis. Other common findings included hypocalcemia, hypomagnesemia, increased potassium in the urine, normal serum creatinine, and normal blood pressure. Consider electrolyte monitoring during treatment. Normalization of electrolyte abnormalities may require drug discontinuation.

PRECAUTIONS

General

Prescribing polymyxin B in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

See **WARNING** box.

Baseline renal function should be done prior to therapy, with frequent monitoring of renal function and blood levels of the drug during parenteral therapy.

Avoid concurrent use of a curariform muscle relaxant and other neurotoxic drugs (ether, tubocurarine, succinylcholine, gallamine, decamethonium and sodium citrate) which may precipitate respiratory depression. If signs of respiratory paralysis appear, respiration should be assisted as required, and the drug discontinued.

As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi.

If superinfection occurs, appropriate therapy should be instituted

Information for Patients

Patients should be counseled that antibacterial drugs including polymyxin B should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When polymyxin B is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.

Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by polymyxin B or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

ADVERSE REACTIONS

See **WARNING** box.

Nephrotoxic reactions

Albuminuria, cylinduria, azotemia, and rising blood levels without any increase in dosage.

Renal system reactions

electrolyte and acid/base abnormalities (i.e., Pseudo-Bartter syndrome)

Neurotoxic reactions

Facial flushing, dizziness progressing to ataxia, drowsiness, peripheral paresthesias (circumoral and stocking glove), apnea due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdose, and signs of meningeal irritation with intrathecal administration, e.g., fever, headache, stiff neck and increased cell count and protein cerebrospinal fluid.

Other reactions occasionally reported

Drug fever, urticarial rash, pain (severe) at intramuscular injection sites, and thrombophlebitis at intravenous injection sites.

To report SUSPECTED ADVERSE REACTIONS, contact Xellia Pharmaceuticals Inc at safety@xellia.com or 1-833-295-6953, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

PARENTERAL

Intravenous

Dissolve 500,000 polymyxin B units in 300 to 500 mL solutions for parenteral 5% Dextrose Injection for continuous drip.

Adults and children

15,000 to 25,000 units/kg body weight/day in individuals with normal kidney function. This amount should be reduced from 15,000 units/kg downward for individuals with kidney impairment. Infusions may be given every 12 hours; however, the total daily dose must not exceed 25,000 units/kg/day.

Infants

Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.

Intramuscular

Not recommended routinely because of severe pain at injection sites, particularly in infants and children. Dissolve 500,000 Polymyxin B units in 2 mL Sterile Water for Injection or 0.9 % Sodium Chloride Injection or Procaine Hydrochloride Injection 1%.

Adults and children

25,000 to 30,000 units/kg/day. This should be reduced in the presence of renal impairment. The dosage may be divided and given at either 4 or 6 hour intervals.

Infants

Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.

Note: Doses as high as 45,000 units/kg/day have been used in limited clinical studies in treating prematures and newborn infants for sepsis caused by *Ps aeruginosa*.

Intrathecal

A treatment of choice for *Ps aeruginosa* meningitis.

Dissolve 500,000 polymyxin B units in 10 mL 0.9 % Sodium Chloride Injection USP for 50,000 units per mL dosage unit.

Adults and children over 2 years of age

Dosage is 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.

Children under 2 years of age

20,000 units once daily, intrathecally for 3 to 4 days or 25,000 units once every other day. Continue with a dose of 25,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.

IN THE INTEREST OF SAFETY, SOLUTIONS OF PARENTERAL USE SHOULD BE STORED UNDER REFRIGERATION, AND ANY UNUSED PORTIONS SHOULD BE DISCARDED AFTER 72 HOURS.

TOPICAL

Ophthalmic

Dissolve 500,000 polymyxin B units in 20 to 50 mL sterile water for injection or 0.9% sodium chloride injection, USP for a 10,000 to 25,000 units per mL concentration.

For the treatment of *Ps aeruginosa* infections of the eye, a concentration of 0.1 percent to 0.25 percent (10,000 units to 25,000 units per mL) is administered 1 to 3 drops every hour, increasing the intervals as response indicates.

Subconjunctival injection of up to 100,000 units/day may be used for the treatment of *Ps aeruginosa* infections of the cornea and conjunctiva.

Note: Avoid total systemic and ophthalmic instillation over 25,000 units/kg/day.

HOW SUPPLIED

Each vial of Polymyxin B for Injection contains polymyxin B sulfate equivalent to 500,000 polymyxin B units. It is supplied in rubber-stoppered glass vial with flip off cap, as a single-vial carton (NDC 70594-049-01) and ten vials per carton (NDC 70594-049-02).

Storage recommendations

Before reconstitution

Store at 20° to 25°C (68° to 77°F) (See USP controlled Room Temperature)

Protect from light. Retain in carton until time of use.

After reconstitution

Product must be stored under refrigeration, between 2° to 8°C (36° to 46°F) and any unused portion should be discarded after 72 hours.

Manufactured for:

Xellia Pharmaceuticals Inc

Beachwood, OH 44122

Made in Hyderabad, Telangana, India

Revised: May 2025

1313000075-03

Code No: AP/DRUGS/103/97

PRINCIPAL DISPLAY PANEL - 500,000 unit Vial Carton

NDC - 70594-049-02

Rx Only

Polymyxin B for Injection, USP

500,000 units per vial

10 sterile vials

FOR HOSPITAL USE ONLY,

if prescribed for intramuscular, intravenous,
and/or intrathecal administration.

Each vial contains Polymyxin B Sulfate
equivalent to 500,000 polymyxin B units

Sterile

Lyophilized

xellia

PHARMACEUTICALS

NDC - 70594-049-02

Rx Only

Polymyxin B for Injection, USP



500,000 units per vial

10 sterile vials

FOR HOSPITAL USE ONLY,
if prescribed for intramuscular, intravenous,
and/or intrathecal administration.

Each vial contains Polymyxin B Sulfate
equivalent to 500,000 polymyxin B units

Sterile Lyophilized



Manufactured for:
Xellia Pharmaceuticals Inc
Beachwood, OH 44122

Made in Hyderabad, Telangana,
India

Code No: AP/DRUGS/103/97



101100370594049021



FOR HOSPITAL USE ONLY, 10 sterile vials
if prescribed for intramuscular,
intravenous, and/or intrathecal
administration.



Sterile Lyophilized

500,000 units per vial

Polymyxin B for Injection, USP

Rx Only

NDC - 70594-049-02

GTIN 00370594049021
SN NNNNNNNNNNN
LOT AXXXXXX
EXP YYYY-MM

FPO
2D

1312000430-03

Usual Dosage: See package insert. Dosages should not exceed
25,000 units per kg per day.

WARNING: This drug may be neuro- and nephrotoxic.
Administer by the intramuscular, intravenous, and/or intrathecal routes
in hospitalized patients only.

Storage: Before Reconstitution: Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature]. **Protect from light.**

After Reconstitution: Product must be stored under refrigeration,
between 2° to 8°C (36° to 46°F) and any unused portion should be
discarded after 72 hours.

NDC - 70594-049-02

Polymyxin B for Injection, USP


500,000 units per vial

Each vial contains Polymyxin B
Sulfate equivalent to 500,000
polymyxin B units



10 sterile vials





PRINCIPAL DISPLAY PANEL - 500,000 unit Vial Label

NDC 70594-049-01

Polymyxin B
for Injection, USP

500,000 units per vial

FOR HOSPITAL USE ONLY,
if prescribed for intramuscular,
intravenous, and/or intrathecal
administration.

Rx Only

Sterile
Lyophilized

NDC 70594-049-01	Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin units.	 101100370594049014	Discard After
Polymyxin B for Injection, USP	Usual Dosage: See package insert. Dosages should not exceed 25,000 units per kg per day.		Mfd. for: Xellia Pharmaceuticals Inc. Beachwood, OH 44122 Made in Hyderabad, Telangana, India Code No: AP/DRUGS/103/97
500,000 units per vial	WARNING: This drug may be neuro- and nephrotoxic. Administer by the intramuscular, intravenous, and/or intrathecal routes in hospitalized patients only.		1311000489-03
FOR HOSPITAL USE ONLY, if prescribed for intramuscular, intravenous, and/or intrathecal administration.	STORAGE: Before Reconstitution: Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Protect from light.		Un varnish area 20 x 12 mm
Rx Only	After reconstitution: Product must be stored under refrigeration, between 2° to 8°C (36° to 46°F), and any unused portion should be discarded after 72 hours.		
Sterile Lyophilized 			Lot: Exp:

PRINCIPAL DISPLAY PANEL - 500,000 unit Vial Carton - 049-01

NDC 70594-049-01

Rx Only

Polymyxin B
for Injection, USP


500,000 units per vial

FOR HOSPITAL USE ONLY,

if prescribed for intramuscular, intravenous, and/or intrathecal administration.

xellia
PHARMACEUTICALS

Sterile
Lyophilized
1 sterile vial



POLYMYXIN B

polymyxin b sulfate injection, powder, for solution

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:70594-049
Route of Administration	INTRAMUSCULAR, INTRATHECAL, OPHTHALMIC, INTRAVENOUS		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
POLYMYXIN B SULFATE (UNII: 19371312D4) (POLYMYXIN B - UNII:J2VZ.07J96K)	POLYMYXIN B	500000 [USP'U]

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70594-049-02	10 in 1 CARTON	10/01/2018	
1		1 in 1 VIAL, GLASS; Type 0: Not a Combination Product		
2	NDC:70594-049-01	1 in 1 CARTON	10/01/2018	
2		1 in 1 VIAL, GLASS; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA202766	10/01/2018	

Labeler - Xellia Pharmaceuticals USA LLC (116768762)

Registrant - Xellia Pharmaceuticals ApS (305814345)

Revised: 4/2025

Xellia Pharmaceuticals USA LLC